LG Display Co. reported a net profit of 621 billion won in the fourth quarter, swinging from a loss of 1.81 trillion won last year due to an increased demand of its panels for IT products and sales of OLED displays amid the stay-at-home trend.
The company's fourth-quarter operating income jumped to 685.5 billion won, from a loss of 421.9 billion won a year ago, surpassing the market consensus of 377.3 billion won.
Sales soared 16.2 percent on-year to 7.46 trillion won, which was also higher than the expected 7.25 trillion won.
However, LG Display reported a net loss of 70.6 billion won for the entire 2020, sharply narrowing from the previous year's net loss of 691.6 billion won.
Operating losses also narrowed to 29.1 billion won from 714.5 billion won, while sales rose 3.2 percent on-year to 24.23 trillion won in 2020.


DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Trump Urges Iran to Sign Nuclear Deal Amid Ongoing Conflict and Port Blockade
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
China Factory Activity Extends Growth in April Despite Global Pressures
US Sanctions Target Iran’s Shadow Banking Network and Terror Financing
Australia Inflation Surges in March as Fuel Prices Spike Amid Middle East Conflict
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Gold Prices Fall as Strong Dollar and Rising Oil Prices Pressure Markets
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears
US Stock Futures Mixed as Fed Holds Rates, Oil Prices Surge, and Big Tech Earnings Drive Market Moves
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



